CoChat
Sign Up
Cited by 120Malaria Research and ControlBird parasitology and diseasesHemoglobinopathies and Related Disorders

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso

Open access
Tiono, Alfred B, Ouédraogo, Alphonse, Ogutu, Bernhards, Diarra, Amidou, Coulibaly, Sam, Gansané, Adama, Sirima, Sodiomon B, O’Neil, Gregory, Mukhopadhyay, Amitava, Hamed, Kamal·2013·Malaria Journal
DOI 10.1186/1475-2875-12-79PMC PMC3599538
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: In malaria-endemic countries, large proportions of infected individuals are asymptomatic, constituting a reservoir of parasites for infection of newly hatched mosquitoes. This study evaluated the impact of screening and treatment of asymptomatic carriers of Plasmodium falciparum. METHODS: Eighteen villages were randomized (1:1) to study arms and inhabitants participated in four community screening campaigns: three before the rainy season ~1 month apart, and the fourth after the rains at ~12 months. On day 1 of campaigns 1-3, asymptomatic carriers in the intervention arm were identified by rapid diagnostic test and treated with artemether-lumefantrine. Outcomes were symptomatic malaria with parasite density >5,000/μL per person-year in children < 5 years and change in haemoglobin between days 1 and 28 of campaign 1. RESULTS: At 12 months, the number of symptomatic malaria episodes with a parasite density >5,000/μL per person-year in children < 5 years was not significantly different between arms (1.69 vs 1.60, p = 0.3482). Mean haemoglobin change in asymptomatic carriers during campaign 1 was greater in the intervention vs control arm (+0.53 g/dL vs -0.21 g/dL, p < 0.0001). ANCOVA demonstrated that mean asymptomatic carriage at the cluster level was lower in the intervention vs control arm at day 1 of campaigns 2 (5.0% vs 34.9%, p < 0.0001) and 3 (3.5% vs 31.5%, p < 0.0001), but showed only a small difference at day 1 of campaign 4 (34.6% vs 37.6%, p = 0.2982). Mean gametocyte carriage was lower in the intervention vs control arm at day 1 of campaigns 2 and 3 (0.7% vs 5.4%, p < 0.0001; 0.5% vs 5.8%, p < 0.0001), but was similar at day 1 of campaign 4 (4.9% vs 5.1%, p = 0.7208). CONCLUSIONS: Systematic screening and treatment of asymptomatic carriers at the community level did not reduce clinical malaria incidence in the subsequent transmission season, indicating greater levels of parasite clearance are required to achieve a sustained impact in this setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2875-12-79

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Map of the Saponé demographic surveillance system area. The control clusters are represented by circles whereas intervention clusters are represented by squares.
Figure 1 Map of the Saponé demographic surveillance system area. The control clusters are represented by circles whereas intervention clusters are represented by squares.CC BY · PubMed Central
Figure 2 Study design.
Figure 2 Study design.CC BY · PubMed Central
Figure 3 Flow chart showing numbers of participants throughout the study – trial profile.
Figure 3 Flow chart showing numbers of participants throughout the study – trial profile.CC BY · PubMed Central
Figure 4 Symptomatic malaria episodes with a parasite density >5,000/μL (SMRC5000) per person-year in children aged < 5 years.
Figure 4 Symptomatic malaria episodes with a parasite density >5,000/μL (SMRC5000) per person-year in children aged < 5 years.CC BY · PubMed Central
Figure 5 ANCOVA results for prevalence of microscopy-confirmed asymptomatic carriers.
Figure 5 ANCOVA results for prevalence of microscopy-confirmed asymptomatic carriers.CC BY · PubMed Central
Figure 6 ANCOVA results for prevalence of microscopy-confirmed gametocyte carriers.
Figure 6 ANCOVA results for prevalence of microscopy-confirmed gametocyte carriers.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. WHO: WHO Model List of Essential Medicines. 2010, Geneva: World Health Organization
  2. Mapping Malaria Risk in Africa (MARA) Collaboration: Burkina Faso: Duration of the Malaria Transmission Season. 2012, http://www.mara.org.za/pdfmaps/BukSeasonality.PDF , 10-6-2010.

Cited by

Sorted by citations

See all 120

Related

See all

Metadata

Authors
Tiono, A. B., Ouédraogo, A., Ogutu, B., Diarra, A., Coulibaly, S., Gansané, A., Sirima, S. B., O’Neil, G., Mukhopadhyay, A., & Hamed, K.
Affiliations
  • Centre National de Recherche et de Formation sur le Paludisme (BF)
  • Kenya Medical Research Institute (KE)
  • Novartis (Switzerland) (CH)
  • Novartis (India) (IN)
Corresponding author
Tiono, Alfred B
ORCID
Venue
Malaria Journal
Publisher
Springer Science and Business Media LLC
Published
2013-02-27
Volume
12
Issue
1
Pages
79-79
ISSN
1475-2875 (ISSN-L)
DOI
10.1186/1475-2875-12-79
PMC
PMC3599538
OpenAlex
W2097232649
Cited by
118
References
24
Citations by year
2026: 2 · 2025: 1 · 2024: 6 · 2023: 8 · 2022: 2 · 2021: 2 · 2020: 19 · 2019: 7 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 15 · 2014: 15 · 2013: 6
FWCI
17.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Novartis Pharma
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Parasitology › Bird parasitology and diseases
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
Plasmodium falciparum, asymptomatic malaria, asymptomatic carriers, artemether-lumefantrine, gametocyte carriage, malaria transmission, malaria reservoir, hemoglobin, children under five, rapid diagnostic tests, malaria elimination, Burkina Faso, malaria-endemic countries
MeSH terms
Artemether, Lumefantrine Drug Combination, Adolescent, Adult, Aged, Aged, 80 and over, Antimalarials, Burkina Faso, Carrier State, Child, Child, Preschool, Drug Combinations, Ethanolamines, Female, Fluorenes, Humans, Infant, Male, Mass Screening, Middle Aged, Pregnancy, Rural Population, Incidence, Malaria, Falciparum, Treatment Outcome, Clinical Laboratory Techniques, Artemisinins, Young Adult, Asymptomatic Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review